BWA
CGEM icon

Basecamp Wealth Advisors’s Cullinan Oncology CGEM Stock Holding History

Basecamp Wealth Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255 Sell
14
-13
-48% -$193 ﹤0.01% 1724
2026
Q1 		$384 Buy
+27
New +$347 ﹤0.01% 1778

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Basecamp Wealth Advisors's CGEM Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Cullinan Oncology (CGEM) stake by 48% in Q2 2026, selling an estimated $193 and leaving 14 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

Basecamp Wealth Advisors first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. The position peaked at $384 in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Basecamp Wealth Advisors held 14 shares of Cullinan Oncology worth $255 as of Q2 2026.
  • Basecamp Wealth Advisors sold 13 Cullinan Oncology shares in Q2 2026, an estimated $193.
  • Cullinan Oncology made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1724 holding.
  • Basecamp Wealth Advisors first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Cullinan Oncology position peaked at $384 in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.